Cargando…
Human antibody profiling technologies for autoimmune disease
Autoimmune diseases are caused by the break-down in self-tolerance mechanisms and can result in the generation of autoantibodies specific to human antigens. Human autoantigen profiling technologies such as solid surface arrays and display technologies are powerful high-throughput technologies utilis...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870766/ https://www.ncbi.nlm.nih.gov/pubmed/36690876 http://dx.doi.org/10.1007/s12026-023-09362-8 |
_version_ | 1784877038509752320 |
---|---|
author | Carlton, Lauren H. McGregor, Reuben Moreland, Nicole J. |
author_facet | Carlton, Lauren H. McGregor, Reuben Moreland, Nicole J. |
author_sort | Carlton, Lauren H. |
collection | PubMed |
description | Autoimmune diseases are caused by the break-down in self-tolerance mechanisms and can result in the generation of autoantibodies specific to human antigens. Human autoantigen profiling technologies such as solid surface arrays and display technologies are powerful high-throughput technologies utilised to discover and map novel autoantigens associated with disease. This review compares human autoantigen profiling technologies including the application of these approaches in chronic and post-infectious autoimmune disease. Each technology has advantages and limitations that should be considered when designing new projects to profile autoantibodies. Recent studies that have utilised these technologies across a range of diseases have highlighted marked heterogeneity in autoantibody specificity between individuals as a frequent feature. This individual heterogeneity suggests that epitope spreading maybe an important mechanism in the pathogenesis of autoimmune disease in general and likely contributes to inflammatory tissue damage and symptoms. Studies focused on identifying autoantibody biomarkers for diagnosis should use targeted data analysis to identify the rarer public epitopes and antigens, common between individuals. Thus, utilisation of human autoantigen profiling technology, combined with different analysis approaches, can illuminate both pathogenesis and biomarker discovery. |
format | Online Article Text |
id | pubmed-9870766 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-98707662023-01-25 Human antibody profiling technologies for autoimmune disease Carlton, Lauren H. McGregor, Reuben Moreland, Nicole J. Immunol Res Review Autoimmune diseases are caused by the break-down in self-tolerance mechanisms and can result in the generation of autoantibodies specific to human antigens. Human autoantigen profiling technologies such as solid surface arrays and display technologies are powerful high-throughput technologies utilised to discover and map novel autoantigens associated with disease. This review compares human autoantigen profiling technologies including the application of these approaches in chronic and post-infectious autoimmune disease. Each technology has advantages and limitations that should be considered when designing new projects to profile autoantibodies. Recent studies that have utilised these technologies across a range of diseases have highlighted marked heterogeneity in autoantibody specificity between individuals as a frequent feature. This individual heterogeneity suggests that epitope spreading maybe an important mechanism in the pathogenesis of autoimmune disease in general and likely contributes to inflammatory tissue damage and symptoms. Studies focused on identifying autoantibody biomarkers for diagnosis should use targeted data analysis to identify the rarer public epitopes and antigens, common between individuals. Thus, utilisation of human autoantigen profiling technology, combined with different analysis approaches, can illuminate both pathogenesis and biomarker discovery. Springer US 2023-01-24 2023 /pmc/articles/PMC9870766/ /pubmed/36690876 http://dx.doi.org/10.1007/s12026-023-09362-8 Text en © The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Carlton, Lauren H. McGregor, Reuben Moreland, Nicole J. Human antibody profiling technologies for autoimmune disease |
title | Human antibody profiling technologies for autoimmune disease |
title_full | Human antibody profiling technologies for autoimmune disease |
title_fullStr | Human antibody profiling technologies for autoimmune disease |
title_full_unstemmed | Human antibody profiling technologies for autoimmune disease |
title_short | Human antibody profiling technologies for autoimmune disease |
title_sort | human antibody profiling technologies for autoimmune disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870766/ https://www.ncbi.nlm.nih.gov/pubmed/36690876 http://dx.doi.org/10.1007/s12026-023-09362-8 |
work_keys_str_mv | AT carltonlaurenh humanantibodyprofilingtechnologiesforautoimmunedisease AT mcgregorreuben humanantibodyprofilingtechnologiesforautoimmunedisease AT morelandnicolej humanantibodyprofilingtechnologiesforautoimmunedisease |